Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

PURPOSE: The prostate-specific membrane antigen (PSMA) has emerged as an interesting target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). The aim of this study was to investigate (161)Tb (T(1/2) = 6.89 days; Eβ(-)uperscript>(av) = 154 keV) in combination w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Nucl Med Mol Imaging
Autors principals: Müller, Cristina, Umbricht, Christoph A., Gracheva, Nadezda, Tschan, Viviane J., Pellegrini, Giovanni, Bernhardt, Peter, Zeevaart, Jan Rijn, Köster, Ulli, Schibli, Roger, van der Meulen, Nicholas P.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6820371/
https://ncbi.nlm.nih.gov/pubmed/31134301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-019-04345-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars